{
    "root": "308a5e30-cd1a-0f17-e063-6394a90ab556",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "STELARA",
    "value": "20250317",
    "ingredients": [
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "USTEKINUMAB",
            "code": "FU77B4U5Z0"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "METHIONINE",
            "code": "AE28F7PNPL"
        }
    ],
    "indications": "stelara ® human interleukin-12 -23 antagonist indicated treatment : adult patients : moderate severe plaque psoriasis ( pso ) candidates phototherapy systemic therapy . ( 1.1 ) active psoriatic arthritis ( psa ) . ( 1.2 ) moderately severely active crohn 's disease ( cd ) . ( 1.3 ) moderately severely active ulcerative colitis . ( 1.4 ) pediatric patients 6 years older : moderate severe plaque psoriasis , candidates phototherapy systemic therapy . ( 1.1 ) active psoriatic arthritis ( psa ) . ( 1.2 )",
    "contraindications": "psoriasis adult subcutaneous recommended ( 2.1 ) : weight range ( kilograms ) dose less equal 100 kg 45 mg administered subcutaneously initially 4 weeks later , followed 45 mg administered subcutaneously every 12 weeks greater 100 kg 90 mg administered subcutaneously initially 4 weeks later , followed 90 mg administered subcutaneously every 12 weeks psoriasis pediatric patients ( 6 17 years old ) subcutaneous recommended ( 2.1 ) : weight-based dosing recommended initial dose , 4 weeks later , every 12 weeks thereafter . weight range ( kilograms ) dose less 60 kg 0.75 mg/kg 60 kg 100 kg 45 mg greater 100 kg 90 mg psoriatic arthritis adult subcutaneous recommended ( 2.2 ) : recommended 45 mg administered subcutaneously initially 4 weeks later , followed 45 mg administered subcutaneously every 12 weeks . patients co-existent moderate-to-severe plaque psoriasis weighing greater 100 kg , recommended 90 mg administered subcutaneously initially 4 weeks later , followed 90 mg administered subcutaneously every 12 weeks . psoriatic arthritis pediatric ( 6 17 years old ) subcutaneous recommended ( 2.2 ) : weight-based dosing recommended initial dose , 4 weeks later , every 12 weeks thereafter . weight range ( kilograms ) dose less 60 kg 0.75 mg/kg 60 kg 45 mg greater 100 kg co-existent moderate-to-severe plaque psoriasis 90 mg crohn 's disease ulcerative colitis initial adult intravenous recommended ( 2.3 ) : single intravenous infusion using weight-based dosing : weight range ( kilograms ) recommended 55 kg 260 mg ( 2 vials ) greater 55 kg 85 kg 390 mg ( 3 vials ) greater 85 kg 520 mg ( 4 vials ) crohn 's disease ulcerative colitis maintenance adult subcutaneous recommended ( 2.3 ) : subcutaneous 90 mg dose 8 weeks initial intravenous dose , every 8 weeks thereafter .",
    "warningsAndPrecautions": "stelara ® ( ustekinumab ) injection sterile , preservative-free , colorless light yellow solution may contain small translucent white particles . supplied individually packaged , single-dose prefilled syringes single-dose vials .",
    "adverseReactions": "stelara ®is contraindicated patients clinically significant hypersensitivity ustekinumab excipients stelara ® [ ( 5.5 ) ] .",
    "indications_original": "STELARA ® is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )",
    "contraindications_original": "Psoriasis Adult Subcutaneous Recommended Dosage ( 2.1 ) : Weight Range (kilograms) Dose less than or equal to 100 kg 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks greater than 100 kg 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks Psoriasis Pediatric Patients (6 to 17 years old) Subcutaneous Recommended Dosage ( 2.1 ) : Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter. Weight Range (kilograms) Dose less than 60 kg 0.75 mg/kg 60 kg to 100 kg 45 mg greater than 100 kg 90 mg Psoriatic Arthritis Adult Subcutaneous Recommended Dosage ( 2.2 ): The recommended dosage is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks. For patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg, the recommended dosage is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks. Psoriatic Arthritis Pediatric (6 to 17 years old) Subcutaneous Recommended Dosage ( 2.2 ): Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter. Weight Range (kilograms) Dose less than 60 kg 0.75 mg/kg 60 kg or more 45 mg greater than 100 kg with co-existent moderate-to-severe plaque psoriasis 90 mg Crohn's Disease and Ulcerative Colitis Initial Adult Intravenous Recommended Dosage ( 2.3 ) : A single intravenous infusion using weight-based dosing: Weight Range (kilograms) Recommended Dosage up to 55 kg 260 mg (2 vials) greater than 55 kg to 85 kg 390 mg (3 vials) greater than 85 kg 520 mg (4 vials) Crohn's Disease and Ulcerative Colitis Maintenance Adult Subcutaneous Recommended Dosage ( 2.3 ) : A subcutaneous 90 mg dose 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.",
    "warningsAndPrecautions_original": "STELARA\n \n  ®(ustekinumab) injection is a sterile, preservative-free, colorless to light yellow solution and may contain a few small translucent or white particles. It is supplied as individually packaged, single-dose prefilled syringes or single-dose vials.",
    "adverseReactions_original": "STELARA\n \n  ®is contraindicated in patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients in STELARA\n \n  ®\n                     [see\n  \n   Warnings and Precautions (5.5)]."
}